Key Points
- Director Gilbert Fuller sold 1,058 shares on March 20 at an average price of $17.00, for a total of $17,986, per an SEC Form 4 filing.
- USANA beat quarterly expectations with $0.60 EPS vs. $0.41 expected and revenue of $226.2M, but reported a low net margin (1.16%) and modest ROE (6.75%), and the stock's consensus analyst rating is currently "Reduce."
- Shares opened at $16.88 (down ~1.5%), trading near their 12‑month low ($16.72) with a market cap of about $311.6M and 50/200‑day moving averages of $20.29/$21.88.
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Gilbert Fuller sold 1,058 shares of the firm's stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $17.00, for a total value of $17,986.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
USANA Health Sciences Trading Down 1.5%
USANA Health Sciences stock opened at $16.88 on Friday. The firm has a 50 day moving average of $20.29 and a 200 day moving average of $21.88. The firm has a market capitalization of $311.61 million, a price-to-earnings ratio of 30.70, a P/E/G ratio of 0.71 and a beta of 0.64. USANA Health Sciences, Inc. has a 12-month low of $16.72 and a 12-month high of $38.32.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. The company had revenue of $226.20 million for the quarter, compared to analysts' expectations of $225.96 million. On average, analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.
Analyst Ratings Changes
A number of research firms recently weighed in on USNA. Zacks Research upgraded shares of USANA Health Sciences from a "strong sell" rating to a "hold" rating in a research note on Monday, February 16th. Weiss Ratings reiterated a "sell (d)" rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Finally, Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Reduce".
View Our Latest Stock Report on USANA Health Sciences
Institutional Investors Weigh In On USANA Health Sciences
A number of institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC bought a new stake in shares of USANA Health Sciences during the fourth quarter valued at approximately $11,485,000. Millennium Management LLC boosted its position in shares of USANA Health Sciences by 715.7% during the fourth quarter. Millennium Management LLC now owns 285,416 shares of the company's stock worth $5,603,000 after acquiring an additional 250,424 shares during the last quarter. Two Sigma Investments LP grew its stake in USANA Health Sciences by 349.8% during the third quarter. Two Sigma Investments LP now owns 160,933 shares of the company's stock valued at $4,434,000 after acquiring an additional 125,158 shares in the last quarter. UBS Group AG grew its stake in USANA Health Sciences by 252.3% during the fourth quarter. UBS Group AG now owns 138,334 shares of the company's stock valued at $2,715,000 after acquiring an additional 99,063 shares in the last quarter. Finally, Tudor Investment Corp ET AL increased its holdings in USANA Health Sciences by 354.8% in the 4th quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company's stock valued at $2,153,000 after acquiring an additional 85,570 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
